Predictive and prognostic survival analysis in a cohort of colorectal cancer patients

Aberrant changes in key genes and biological pathways, such as Wnt signal transduction and DNA damage response, have been shown to modify disease outcomes in patients with metastatic colorectal cancer (mCRC; Xue et al., 2025, Signal Transduct Target Ther; Amodio et al., 2024, Br J Cancer). Furthermore, the identification of specific genetic alterations in key oncogenic drivers can provide an insight into the genetic determinants of patient outcomes and the development of precision oncology treatments and drug targets.

In this report, we investigated progression-free survival (PFS) and overall survival (OS) in a cohort of colorectal cancer patients to determine if mutations in individual genes, or tumour mutational burden (TMB), led to better survival outcomes following treatment with fluoropyrimidine + irinotecan +/- bevacizumab (BEV) compared to fluoropyrimidine + oxaliplatin +/- BEV. We assessed survival using predictive and prognostic models.

To request this predictive and prognostic survival analysis sample report, complete the form below: